1. 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk. (9th November 2020) Authors: Choueiri, Toni; Albiges, Laurence; Powles, Thomas; Mohamed, Nehal; Wang, Fong; Motzer, Robert Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Issue 1 (January 2016) Authors: Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; Hájek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; Rosiñol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel,... Journal: Lancet oncology Issue: Volume 17:Issue 1(2016:Feb.) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Issue 10 (3rd October 2017) Authors: Ludwig, Heinz; Dimopoulos, Meletios A.; Moreau, Philippe; Chng, Wee-Joo; Goldschmidt, Hartmut; Hájek, Roman; Facon, Thierry; Pour, Ludek; Niesvizky, Ruben; Oriol, Albert; Rosiñol, Laura; Suvorov, Aleksandr; Gaidano, Gianluca; Pika, Tomas; Weisel, Katja; Goranova-Marinova, Vesselina; Palumbo, Anto... Journal: Leukemia & lymphoma Issue: Volume 58:Issue 10(2017) Page Start: 2501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗